Biotech News

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

T2 Biosystems (TTOO)T2 Biosystems2025-01-07 14:00 ESTEarnings

Achieved record fourth quarter and full-year 2024 sepsis product revenues LEXINGTON, Mass. , Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced

Related news

MDXHMDxHealth2026-01-12 13:00 EST

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

BDSXBiodesix2026-01-12 11:00 EST

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

LUCDLucid Diagnostics2026-03-26 12:00 EST

Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

SERASera Prognostics2026-03-18 20:05 EST

SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

FLGTFulgent Genetics, Inc.2026-02-27 12:00 EST

Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

MDXHMDxHealth2026-02-26 21:00 EST

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results

XGNExagen2026-02-24 14:00 EST

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

FLGTFulgent Genetics, Inc.2026-02-12 12:30 EST

Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026

BDSXBiodesix2026-02-12 11:00 EST

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

DGXQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

View all latest news

T2 Biosystems

T2 Biosystems is a medical diagnostics company focused on rapid pathogen detection and bloodstream infection testing. Its business is centered on delivering fast diagnostic information to clinical settings.

Recent company news

TTOOT2 Biosystems2025-01-07 14:00 EST

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

TTOOT2 Biosystems2024-12-18 14:00 EST

T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

TTOOT2 Biosystems2024-12-17 14:00 EST

T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

TTOOT2 Biosystems2024-12-16 14:00 EST

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

TTOOT2 Biosystems2024-12-09 14:00 EST

T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens

Stock data

Close: 0.00 USD
Market cap: —
Exchange: NASDAQ
Sector: MedTech
Location: United States